Alza Corporation, DE, USA [clinicaltrials_resource:c57cac1672cf19ddd82f3ce65c6669a7]
affiliation [clinicaltrials_vocabulary:affiliation]
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00264485]A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00266539]
collaborator [clinicaltrials_vocabulary:collaborator]
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation [clinicaltrials:NCT00211094]A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation. [clinicaltrials:NCT00211107]A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00264485]A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00266539]A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence [clinicaltrials:NCT00269724]Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer [clinicaltrials:NCT00269737]A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. [clinicaltrials:NCT00269750]Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer [clinicaltrials:NCT00269763]An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269776]A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children [clinicaltrials:NCT00269789]A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269802]Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269815]Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder [clinicaltrials:NCT00293839]Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence [clinicaltrials:NCT00304499]Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis [clinicaltrials:NCT00396422]A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain [clinicaltrials:NCT00398788]An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg [clinicaltrials:NCT00398957]An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release) [clinicaltrials:NCT00399048]An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg [clinicaltrials:NCT00399295]A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients. [clinicaltrials:NCT00410540]A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain [clinicaltrials:NCT00410644]Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release) [clinicaltrials:NCT00410748]Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain [clinicaltrials:NCT00410787]A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain [clinicaltrials:NCT00410878]Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain [clinicaltrials:NCT00410943]A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain [clinicaltrials:NCT00411034]A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis [clinicaltrials:NCT00411164]Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain [clinicaltrials:NCT00411268]A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain [clinicaltrials:NCT00411307]clinicaltrials:NCT00424931A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant [clinicaltrials:NCT00650182]A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg) [clinicaltrials:NCT00665522]An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients [clinicaltrials:NCT00666393]Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers [clinicaltrials:NCT00714558]Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers [clinicaltrials:NCT00714584]Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System [clinicaltrials:NCT00990418]An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation [clinicaltrials:NCT01230762]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation [clinicaltrials:NCT00211094]A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation. [clinicaltrials:NCT00211107]A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00264485]A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump [clinicaltrials:NCT00266539]A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence [clinicaltrials:NCT00269724]Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer [clinicaltrials:NCT00269737]A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. [clinicaltrials:NCT00269750]Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer [clinicaltrials:NCT00269763]An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269776]A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children [clinicaltrials:NCT00269789]A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269802]Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder [clinicaltrials:NCT00269815]Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder [clinicaltrials:NCT00293839]Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence [clinicaltrials:NCT00304499]Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis [clinicaltrials:NCT00396422]A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain [clinicaltrials:NCT00398788]An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg [clinicaltrials:NCT00398957]An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release) [clinicaltrials:NCT00399048]An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg [clinicaltrials:NCT00399295]A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients. [clinicaltrials:NCT00410540]A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain [clinicaltrials:NCT00410644]Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release) [clinicaltrials:NCT00410748]Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain [clinicaltrials:NCT00410787]A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain [clinicaltrials:NCT00410878]Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain [clinicaltrials:NCT00410943]A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain [clinicaltrials:NCT00411034]A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis [clinicaltrials:NCT00411164]Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain [clinicaltrials:NCT00411268]A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain [clinicaltrials:NCT00411307]clinicaltrials:NCT00424931A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant [clinicaltrials:NCT00650182]A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg) [clinicaltrials:NCT00665522]An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients [clinicaltrials:NCT00666393]Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers [clinicaltrials:NCT00714558]Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers [clinicaltrials:NCT00714584]Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System [clinicaltrials:NCT00990418]An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation [clinicaltrials:NCT01230762]
source [clinicaltrials_vocabulary:source]
Alza Corporation, DE, USA [clinicaltrials_resource:c57cac1672cf19ddd82f3ce65c6669a7]
Bio2RDF identifier
c57cac1672cf19ddd82f3ce65c6669a7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c57cac1672cf19ddd82f3ce65c6669a7
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:c57cac1672cf19ddd82f3ce65c6669a7
title
Alza Corporation, DE, USA
@en
type
label
Alza Corporation, DE, USA [clinicaltrials_resource:c57cac1672cf19ddd82f3ce65c6669a7]
@en